XYDALBA Poudre pour solution

País: Canadá

Idioma: francés

Fuente: Health Canada

Ingredientes activos:

DALBAVANCINE (CHLORHYDRATE DE DALBAVANCINE)

Disponible desde:

ENDO VENTURES LTD.

Código ATC:

J01XA04

Designación común internacional (DCI):

DALBAVANCIN

Dosis:

500MG

formulario farmacéutico:

Poudre pour solution

Composición:

DALBAVANCINE (CHLORHYDRATE DE DALBAVANCINE) 500MG

Vía de administración:

Intraveineuse

Unidades en paquete:

15G/50G

tipo de receta:

Prescription

Área terapéutica:

GLYCOPEPTIDES

Resumen del producto:

Numéro de groupe d'ingrédients actifs (GIA) :0160631001; AHFS:

Estado de Autorización:

APPROUVÉ

Fecha de autorización:

2018-09-04

Ficha técnica

0RQRUDSKLHHSURXL
H
DEDYDQFLQH
3DH
H
0212*53,(
( 3528,7
,1 /817/(65(16(,*1(0(176685 /(0e,
0(17 3285 /(3 7,(17
3U
;< /%
GDOEDYDQFLQH SRXULQMHFWLRQ
PJGHGDOEDYDQFLQH VRXV IRUPHGHFKORUKGUDWHGH GDOEDYDQFLQHIODFRQ
3RXGUHORSKLOLVpHSRXUVROXWLRQ LQWUDYHLQHXVH
JHQW DQWLEDFWpULHQ
DWHGH UpYLVLRQ
DYULO
(QGR9HQXUHV/G
)LUVW )ORRU
0LQHUYDRXVH
6LPPRQVFRXUW5RDG %DOOVEULGJH
XEOLQ
,UODQGH
,PSRU DHXU
OOHUJDQ ,QF
ERXO (QWHUSULVH
0DUNKDP 2QWDULR
/* %
LV ULEXHXU
/DERUDWRLUHV 3DODGLQ
ERXO
OH[LV1LKRQ%XUHDX
6W /DXUHQW 4XpEHF
0 3
1XPpURGHFRQWUOHGHODSUpVHQWDWLRQ
0DUTXHGpSRVpHGH
OOHUJDQ3KDUPDFHXWLFDOV ,QWHUQDWLRQDO/LPLWHG
0RQRUDSKLHHSURXL
H
DEDYDQFLQH
3DH
H
7%/( 8
(60 7,
5(6
357,( ,
5(16(,*1(0(1763285/(352)(66,211(/(/
617e
,1 ,
7,216
(QIDQWV
3HUVRQQHVkJpHV
2175( ,1 ,
7,216
3262/2*,((7
0,1,675 7,21
RQVLGpUDWLRQVSRVRORJLTXHV
RVHUHFRPPDQGpHHW PRGLILFDWLRQSRVRORJLTXH
GPLQLVWUDWLRQ
5HFRQVWLWXWLRQ
68526*(
)250(63262/2*,48(6
21(175 7,216
20326,7,21(7
(0% //*(
0,6(6 (1* 5((735e 87,216
3RSXODWLRQV SDUWLFXOLqUHV
)HPPHV HQFHLQWHV
OODLWHPHQW
(QIDQWV
3HUVRQQHVkJpHV
())(76 ,1e6,5 %/(6
SHUoXGHVHIIHWVLQGpVLUDEOHV
(IIHWVLQGpVLUDEOHV REVHUYpHV GDQV OHVHVVDLV FOLQLTXHV
(IIHWVLQGpVLUDEOHV SHX FRXUDQWVREVHUYpVDX FRXUVGHVHVVDLV FOLQLTXHV
5pVXOWDWVGHODERUDWRLUH DQRUPDX[
KpPDWRORJLTXHFKLPLHFOLQLTXHHW DXWUHV
GRQQpHV TXDQWLWDWLYHV
,17(5
7,2160e,
0(17(86(6
,QWHUDFWLRQVPpGLFDPHQW PpGLFDPHQW
,QWHUDFWLRQV PpGLFDPHQW DOLPHQW
,QWHUDFWLRQV PpGLFDPHQW SODQWHPpGLFLQDOH
,QWHUDFWLRQV PpGLFDPHQW WHVWVGH ODERUDWRLUH
02 (
7,21(7 3
50
2/2*,(
/,1,48(
0RGHG DFWLRQ
3KDUPDFRGQDPLH
3KDUPDFRFLQpWLTXH
(175(326*( 67 %,/,7e(7 75 ,7(0(17
357,( ,,
,1)2507,216,(17,),48(6
,1)250 7,21350 (87,48(6
(66 ,6
/,1,48(6
RQFHSWLRQGHVHVVDLV HW FDUDFWpULVWLTXHV GpPRJUDSKLTXHVGHVpWXGHV
6FKpPD SRVRORJLTXHjGHX[GRVHGH;

Leer el documento completo